Pharma / Biotech

FDA Pulls COVID-19 EUAs for Antimalarial Drugs

Saying that the benefits no longer outweigh the potential risks, the FDA revoked the emergency use authorization (EUA) for hydroxychloroquine sulfate (HCQ) and chloroquine phosphate (CQ) to treat COVID-19.

Source link

Related posts

A once-monthly GLP-1 receptor agonist for treatment of diabetic cats.


MONTELUKAST SODIUM Granule MONTELUKAST SODIUM Tablet, Chewable MONTELUKAST SODIUM (Montelukast) Tablet, Chewable MONTELUKAST SODIUM Tablet, Coated [Ajanta Pharma Limited]


journal pharmacology; +960 new citations


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World